Masimo (NASDAQ:MASI) Announces Quarterly Earnings Results

Masimo (NASDAQ:MASI) announced its earnings results on Tuesday. The medical equipment provider reported $1.32 EPS for the quarter, topping the consensus estimate of $1.20 by $0.12, Zacks reports. The firm had revenue of $371.50 million for the quarter, compared to the consensus estimate of $366.89 million. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The business’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period last year, the company posted $0.86 EPS. Masimo updated its FY 2025 guidance to 5.620-5.790 EPS.

Masimo Stock Down 5.8%

MASI traded down $8.66 during trading on Wednesday, reaching $140.35. 1,064,560 shares of the stock were exchanged, compared to its average volume of 641,570. The stock has a market cap of $7.62 billion, a P/E ratio of -16.31 and a beta of 1.28. Masimo has a twelve month low of $133.70 and a twelve month high of $194.88. The stock’s 50 day moving average price is $144.91 and its two-hundred day moving average price is $154.05. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14.

Analyst Ratings Changes

MASI has been the topic of several research analyst reports. BTIG Research restated a “buy” rating and set a $198.00 target price on shares of Masimo in a report on Wednesday. Zacks Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Wells Fargo & Company dropped their target price on shares of Masimo from $190.00 to $187.00 and set an “overweight” rating on the stock in a report on Wednesday. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Masimo has a consensus rating of “Moderate Buy” and an average price target of $194.00.

Insiders Place Their Bets

In related news, Director William R. Jellison acquired 3,000 shares of the firm’s stock in a transaction on Monday, August 11th. The shares were purchased at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the acquisition, the director directly owned 4,790 shares in the company, valued at approximately $699,244.20. This trade represents a 167.60% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 16.90% of the company’s stock.

Hedge Funds Weigh In On Masimo

Several institutional investors and hedge funds have recently modified their holdings of the business. Thrivent Financial for Lutherans grew its stake in shares of Masimo by 1.7% in the second quarter. Thrivent Financial for Lutherans now owns 10,596 shares of the medical equipment provider’s stock valued at $1,782,000 after acquiring an additional 177 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Masimo by 12.3% in the second quarter. Tower Research Capital LLC TRC now owns 1,516 shares of the medical equipment provider’s stock valued at $255,000 after acquiring an additional 166 shares in the last quarter. Orion Porfolio Solutions LLC lifted its position in Masimo by 2.2% during the second quarter. Orion Porfolio Solutions LLC now owns 4,871 shares of the medical equipment provider’s stock worth $819,000 after purchasing an additional 104 shares during the period. Bamco Inc. NY lifted its position in Masimo by 21.2% during the second quarter. Bamco Inc. NY now owns 384,589 shares of the medical equipment provider’s stock worth $64,696,000 after purchasing an additional 67,307 shares during the period. Finally, AQR Capital Management LLC lifted its position in Masimo by 517.2% during the second quarter. AQR Capital Management LLC now owns 50,256 shares of the medical equipment provider’s stock worth $8,454,000 after purchasing an additional 42,114 shares during the period. 85.96% of the stock is currently owned by institutional investors and hedge funds.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.